QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
NYSE:NVS

Novartis Stock Forecast, Price & News

$85.69
-0.10 (-0.12 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$85.33
Now: $85.69
$86.07
50-Day Range
$85.39
MA: $87.82
$91.00
52-Week Range
$69.18
Now: $85.69
$99.84
Volume1.80 million shs
Average Volume2.12 million shs
Market Capitalization$196.12 billion
P/E Ratio27.29
Dividend Yield2.34%
Beta0.42
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; and Dyno Therapeutics Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Read More
Novartis logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone41-61-324-1111
Employees103,914

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$47.50 billion
Cash Flow$7.85 per share
Book Value$24.53 per share

Profitability

Net Income$11.73 billion

Miscellaneous

Outstanding Shares2,288,700,000
Market Cap$196.12 billion
Next Earnings Date10/27/2020 (Confirmed)
OptionableOptionable
$85.69
-0.10 (-0.12 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novartis (NYSE:NVS) Frequently Asked Questions

How has Novartis' stock price been impacted by Coronavirus (COVID-19)?

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVS shares have increased by 4.3% and is now trading at $85.69.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novartis?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novartis
.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Novartis
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Tuesday, July, 21st. The company reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.31 by $0.05. The business earned $11.35 billion during the quarter, compared to the consensus estimate of $11.77 billion. Novartis had a return on equity of 24.14% and a net margin of 14.96%. The business's revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.34 EPS.
View Novartis' earnings history
.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Monday, February 3rd. Stockholders of record on Wednesday, March 4th will be given a dividend of $3.0425 per share on Thursday, March 12th. This represents a yield of 2%. The ex-dividend date of this dividend is Tuesday, March 3rd. This is a positive change from Novartis's previous annual dividend of $2.86.
View Novartis' dividend history
.

What price target have analysts set for NVS?

10 Wall Street analysts have issued 12 month price objectives for Novartis' stock. Their forecasts range from $100.00 to $116.00. On average, they expect Novartis' stock price to reach $108.00 in the next year. This suggests a possible upside of 26.0% from the stock's current price.
View analysts' price targets for Novartis
.

Are investors shorting Novartis?

Novartis saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 2,470,000 shares, an increase of 14.9% from the August 31st total of 2,150,000 shares. Based on an average trading volume of 1,680,000 shares, the short-interest ratio is presently 1.5 days. Currently, 0.1% of the shares of the stock are sold short.
View Novartis' Short Interest
.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), The Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 44)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 55)
  • Mr. Steffen Lang Ph.D., Global Head of Technical Operations (Age 53)
  • Ms. Shannon Thyme Klinger, Chief Legal Officer (Age 49)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 52)

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Scharf Investments LLC (0.05%), Envestnet Asset Management Inc. (0.04%), Douglas Lane & Associates LLC (0.03%), Gofen & Glossberg LLC IL (0.01%), Confluence Investment Management LLC (0.01%) and Bartlett & Co. LLC (0.01%).

Which major investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Scharf Investments LLC, Verity & Verity LLC, Envestnet Asset Management Inc., CWM LLC, Park National Corp OH, FNY Investment Advisers LLC, Regentatlantic Capital LLC, and Minot Wealth Management LLC.

Which major investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Douglas Lane & Associates LLC, Cardinal Capital Management Inc., Martin Investment Management LLC, Pacer Advisors Inc., Hall Laurie J Trustee, Professional Advisory Services Inc., Crossmark Global Holdings Inc., and Trust Co. of Oklahoma.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $85.69.

How big of a company is Novartis?

Novartis has a market capitalization of $196.12 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.